CN106913669B - 一种治疗胰腺炎的中药组合物及其应用 - Google Patents
一种治疗胰腺炎的中药组合物及其应用 Download PDFInfo
- Publication number
- CN106913669B CN106913669B CN201710286315.0A CN201710286315A CN106913669B CN 106913669 B CN106913669 B CN 106913669B CN 201710286315 A CN201710286315 A CN 201710286315A CN 106913669 B CN106913669 B CN 106913669B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- pancreatitis
- mirabilite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 31
- 241000792859 Enema Species 0.000 claims abstract description 30
- 239000007920 enema Substances 0.000 claims abstract description 30
- 229940095399 enema Drugs 0.000 claims abstract description 30
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 28
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 28
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 28
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 28
- 239000010446 mirabilite Substances 0.000 claims abstract description 28
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 21
- 206010033647 Pancreatitis acute Diseases 0.000 claims abstract description 18
- 201000003229 acute pancreatitis Diseases 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 47
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 26
- 241001673966 Magnolia officinalis Species 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 2
- 244000299790 Rheum rhabarbarum Species 0.000 claims 1
- 235000008216 herbs Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 5
- 240000004980 Rheum officinale Species 0.000 abstract description 3
- 235000008081 Rheum officinale Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 2
- 241000219061 Rheum Species 0.000 description 25
- 244000132619 red sage Species 0.000 description 24
- 238000007796 conventional method Methods 0.000 description 22
- 238000000034 method Methods 0.000 description 18
- 238000000465 moulding Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 11
- 239000004382 Amylase Substances 0.000 description 10
- 102000013142 Amylases Human genes 0.000 description 10
- 108010065511 Amylases Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 235000019418 amylase Nutrition 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 6
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000097 Abdominal tenderness Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗胰腺炎的中药组合物,所述中药组合物是由如下所述重量份的原料药制成:大黄15‑25份、芒硝10‑20份、枳实10‑20份、厚朴10‑20份、桃仁10‑20份、丹参10‑20份。本发明的中药组合物原料药较少,且均为常用中药,原料价廉,制备简便,通过灌肠给药使用方便,避免口服药物的毒副作用,与常规西医配合用于治疗急性胰腺炎,疗效显著。
Description
技术领域
本发明涉及中药技术领域,具体地说,是一种治疗胰腺炎的中药组合物及其应用。
背景技术
急性胰腺炎是由多种病因导致胰酶在胰腺内被激活后引起胰腺组织自身消化、水肿、出血甚至坏死的炎症反应。临床以急性上腹痛、恶心、呕吐、发热和血胰酶增高等为特点。病变程度轻重不等,轻者以胰腺水肿为主,临床多见,病情常呈自限性,预后良好,又称为轻症急性胰腺炎。少数重者的胰腺出血坏死,常继发感染、腹膜炎和休克等,病死率高,称为重症急性胰腺炎。
目前急性胰腺炎除少数病人需外科手术,大部分是内科治疗为主,包括禁食、胃肠减压、补液、镇痛、抗炎、抑制胰腺外分泌及抑制胰酶、应用血管活性物质等。中医药在急性胰腺炎的治疗中逐渐凸显优势。众医家采用经方加减如大柴胡汤、大承气汤等,或是自拟方剂进行了诸多临床实践,临床报道的经验方(柴芍承气汤、清胰汤、茵陈承气汤、健胃清胰汤、清腹通肠冲剂、清肝利胆汤、重胰康、紫花汤、六味汤等)多由经方加减变化而成,取得满意疗效。目前已达成基本共识,在2013年最新版的胰腺炎诊疗指南中明确指出,急性胰腺炎的治疗可结合中医药,但没有给出明确的方药。
中国专利201410119611.8公开了一种用于治疗急性胰腺炎的中药,是由以下重量的药物制成的:柴胡15克、黄芩12克、黄连10克、白芍15克、元胡10克、木香10克、大黄10克、芒硝10克、甘草10克、郁金10克、丹参15克、金银花10克、连翘10克、枳实6克、厚朴6克,该中药见效快,疗效好,对急性胰腺炎有很好的治疗效果。中国专利201410544381.X公开了一种治疗慢性胰腺炎的中药配方,由以下重量份的原料制成:桃仁8-12克、当归8-12克、赤芍8-12克、生地8-12克、大黄8-12克、芒硝8-12克、枳实8-12克、川厚朴8-12克、红花5-8克、川芎5-8克、败酱草15-20克,该中药配方有活血化瘀,清热通腑的功效。然而现有技术中,关于本发明的治疗胰腺炎的灌肠中药方,目前还未见报道。
发明内容
本发明的第一个目的是针对现有技术中的不足,提供一种治疗胰腺炎的中药组合物。
本发明的第二个目的是针对现有技术中的不足,提供如上所述中药组合物的用途。
为实现上述第一个目的,本发明采取的技术方案是:
一种治疗胰腺炎的中药组合物,所述中药组合物是由如下所述重量份的原料药制成:大黄15-25份、芒硝10-20份、枳实10-20份、厚朴10-20份、桃仁10-20份、丹参10-20份。
进一步,所述中药组合物是由如下所述重量份的原料药制成:大黄18-22份、芒硝13-17份、枳实13-17份、厚朴13-17份、桃仁13-17份、丹参13-17份。
进一步,所述中药组合物是由如下所述重量份的原料药制成:大黄20份、芒硝15份、枳实15份、厚朴15份、桃仁l5份、丹参15份。
为实现上述第二个目的,本发明采取的技术方案是:
如上任一所述中药组合物在制备治疗胰腺炎的药物中的应用。
进一步,所述药物的剂型为中药汤剂,通过灌肠给药。
进一步,所述胰腺炎为急性胰腺炎。
进一步,所述药物还包括药学上允许的辅料,所述药学上允许的辅料包括但不限于:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
方解:方中大黄、桃仁清热通腑,活血祛瘀共为君药;芒硝助大黄泻热通便,并能软坚润燥,丹参助桃仁活血通络,共为臣药;积滞内阻,则腑气不通,故以厚朴、枳实行气散结,消痞除满,并助硝、黄推荡积滞以加速热结之排泄,共为佐使。
本发明优点在于:
1、本发明的中药组合物原料药较少,且均为常用中药,原料价廉,且制备简便,通过灌肠给药使用方便,避免口服药物的毒副作用,与常规西医配合用于治疗急性胰腺炎,疗效显著。
2、本发明中药的配比是通过大量实验筛选获得的,具有疗效好、效果更显著的优点。
3、本发明中,中药桃仁其他的中药组分具有协同作用,极大的提高了对血清淀粉酶的改善效果,疗效更佳。
4、本发明的中药组合物由纯中药制成,药味数少且无毒副作用,价格低,易于被患者接受。
具体实施方式
下面结合具体实施方式,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1本发明的中药组合物(一)
按重量份取中药原料:大黄20份、芒硝15份、枳实15份、厚朴15份、桃仁l5份、丹参15份,按照常规方法煎煮。
实施例2本发明的中药组合物(二)
按重量份取中药原料:大黄25份、芒硝10份、枳实10份、厚朴20份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例3本发明的中药组合物(三)
按重量份取中药原料:大黄15份、芒硝20份、枳实20份、厚朴10份、桃仁10份、丹参20份,按照常规方法煎煮。
实施例4本发明的中药组合物(四)
按重量份取中药原料:大黄15份、芒硝10份、枳实10份、厚朴10份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例5本发明的中药组合物(五)
按重量份取中药原料:大黄25份、芒硝10份、枳实10份、厚朴10份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例6本发明的中药组合物(六)
按重量份取中药原料:大黄25份、芒硝20份、枳实10份、厚朴10份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例7本发明的中药组合物(七)
按重量份取中药原料:大黄25份、芒硝20份、枳实20份、厚朴10份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例8本发明的中药组合物(八)
按重量份取中药原料:大黄25份、芒硝20份、枳实20份、厚朴20份、桃仁10份、丹参10份,按照常规方法煎煮。
实施例9本发明的中药组合物(九)
按重量份取中药原料:大黄25份、芒硝20份、枳实20份、厚朴20份、桃仁20份、丹参10份,按照常规方法煎煮。
实施例10本发明的中药组合物(十)
按重量份取中药原料:大黄25份、芒硝20份、枳实20份、厚朴20份、桃仁20份、丹参20份,按照常规方法煎煮。
实施例11本发明的中药组合物(十一)
按重量份取中药原料:大黄18份、芒硝13份、枳实13份、厚朴13份、桃仁13份、丹参13份,按照常规方法煎煮。
实施例12本发明的中药组合物(十二)
按重量份取中药原料:大黄22份、芒硝13份、枳实13份、厚朴13份、桃仁13份、丹参13份,按照常规方法煎煮。
实施例13本发明的中药组合物(十三)
按重量份取中药原料:大黄22份、芒硝17份、枳实13份、厚朴13份、桃仁13份、丹参13份,按照常规方法煎煮。
实施例14本发明的中药组合物(十四)
按重量份取中药原料:大黄22份、芒硝17份、枳实17份、厚朴13份、桃仁13份、丹参13份,按照常规方法煎煮。
实施例15本发明的中药组合物(十五)
按重量份取中药原料:大黄22份、芒硝17份、枳实17份、厚朴17份、桃仁13份、丹参13份,按照常规方法煎煮。
实施例16本发明的中药组合物(十六)
按重量份取中药原料:大黄22份、芒硝17份、枳实17份、厚朴17份、桃仁17份、丹参13份,按照常规方法煎煮。
实施例17本发明的中药组合物(十七)
按重量份取中药原料:大黄22份、芒硝17份、枳实17份、厚朴17份、桃仁17份、丹参17份,按照常规方法煎煮。
实施例18中药组合物(十八)
按重量份取中药原料:大黄30份、芒硝25份、枳实5份、厚朴5份、桃仁5份、丹参5份,按照常规方法煎煮。
实施例19中药组合物(十九)
按重量份取中药原料:大黄10份、芒硝25份、枳实25份、厚朴25份、桃仁25份、丹参25份,按照常规方法煎煮。
实施例20中药组合物(二十)
按重量份取中药原料:大黄20份、芒硝15份、枳实15份、厚朴15份、丹参15份,按照常规方法煎煮。
实施例21中药组合物(二十一)
大黄20份、芒硝15份、枳实15份、厚朴15份、桃仁l5份,按照常规方法煎煮。
需要说明的是,实施例1-21中所述的常规方法煎煮是中药汤剂的常规制作方法,即将所述的原料药加水煎煮至约100mL,制备成灌肠剂备用。
实施例22治疗急性胰腺炎动物试验
1材料
1.1实验动物
健康雄性SD大鼠,年龄11-13周,体重280g~350g,购于中国科学院上海实验动物中心,清洁级。标准条件下喂养,保持手术前至少7天的12小时白-黑周期的环境条件,自由饮食,手术前禁食12小时,术后正常进食直至动物被处死。
1.2实验药物
由本发明实施例1、实施例2、实施例3、实施例18、实施例19、实施例20、实施例21所述中药组合物制备的灌肠剂。
2试验方法
2.1动物分组及模型制作
模型制备:实验前所有大鼠禁食12h,自由饮水。方法:分两次腹腔内注射L-精氨酸(2×2.5g/kg),中间间隔1h,诱导急性胰腺炎模型。
分组:采用随机数字表法随机分为9组,分别为假手术组(空白对照组)、急性胰腺炎模型组(模型组),治疗组一、治疗组二、治疗组三、治疗组四、治疗组五、治疗组六、治疗组七。每组20只。
空白对照组:不给予特殊处理。
模型组:按照上述造模方法,造模后立即灌肠生理盐水1.5mL/kg,1次/12h,共4次。
治疗组一:按照上述造模方法,造模后立即灌肠本发明实施例1制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组二:按照上述造模方法,造模后立即灌肠本发明实施例2制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组三:按照上述造模方法,造模后立即灌肠本发明实施例3制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组四:按照上述造模方法,造模后立即灌肠本发明实施例18制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组五:按照上述造模方法,造模后立即灌肠本发明实施例19制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组六:按照上述造模方法,造模后立即灌肠本发明实施例20制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
治疗组七:按照上述造模方法,造模后立即灌肠本发明实施例21制备的灌肠剂,灌肠1.5mL/kg,灌肠后保留10min,1次/12h,共4次。
上述各组于最后一次用药后处死所有动物,分别留取静脉血和胰腺组织标本检测。
2.2观察指标和方法
(1)采用全自动生化分析仪检测大鼠血清淀粉酶值
(2)采用ELISA试剂盒检测各组大鼠血清中TNF-α,IL-6含量的变化。
3试验结果
(1)各组大鼠血清淀粉酶水平
模型组大鼠血清淀粉酶空白对照组升高(P<0.05),用药干预后,治疗组一、治疗组二、治疗组三血清淀粉酶显著降低(P<0.05或P<0.01),其中治疗组一的降低效果最好。
表1各组大鼠血清淀粉酶水平比较
组别 | n | 血清淀粉酶(U/L) |
空白对照组 | 20 | 1128.12±152.72 |
模型组 | 20 | 2741.30±216.24** |
治疗组一 | 20 | 1281.54±164.60## |
治疗组二 | 20 | 1552.38±172.26# |
治疗组三 | 20 | 1584.02±175.32# |
治疗组四 | 20 | 1967.30±181.52 |
治疗组五 | 20 | 1936.62±187.28 |
治疗组六 | 20 | 2186.34±179.64 |
治疗组七 | 20 | 2162.26±187.18 |
与空白对照组比较,**:P<0.01,*:P<0.05;与模型组比较##:P<0.01,#:P<0.05。
(2)各组大鼠血清TNF-α,IL-6含量的影响。
模型组大鼠血清TNF-α,IL-6含量与空白对照组比较显著升高(P<0.01),用药干预后,治疗组一、治疗组二、治疗组三的TNF-α,IL-6含量显著降低(P<0.05或P<0.01),其中治疗组一的降低效果最好。
表2各组大鼠血清TNF-α,IL-6含量比较
与空白对照组比较,**:P<0.01,*:P<0.05;与模型组比较##:P<0.01,#:P<0.05。
实施例23治疗胰腺炎的临床试验
1临床资料与方法
1.1一般资料
选择我院(上海市第七人民医院)自2015年07月至2016年10月收治的轻、中度急性胰腺炎患者63例,采用随机数字表方法将患者随机分成两组,治疗组33例,男性19例,女性14例,对照组30例,男性16例,女性14例,所有患者均满足2013年中华医学会消化病学分会胰腺疾病学组制定的《中国急性胰腺炎诊治指南》所列的诊断条件,且均在起病72小时内住院治疗。其中有3例患者因自动出院中途退出试验,其中治疗组1例,对照组2例。两组患者性别、年龄及病情程度均无显著性差异。
1.2方法
1.2.1治疗方法
对照组:西医常规治疗,包括(1)减少胰液分泌:禁食、抑制胃酸、生长抑素及其类似物;(2)镇痛,对于疼痛难以忍受的患者可给与哌替啶;(3)预防和抗感染;(4)营养支持。
治疗组:在上述西医治疗的基础上加用本发明实施例1所制备的灌肠剂(将实施例1的中药组合物加水按常规方法煎至约100mL),通过直肠滴入(插入直肠内15cm,滴入时间不少于30min),日一次,根据患者情况连用5-7天。
1.2.2观察指标
(1)临床症状及体征消失时间:腹痛、腹部压痛;
(2)入院后首次排便时间;
(3)化验指标及辅助检査恢复正常时间:血淀粉酶、白细胞计数、CRP。
1.2.3疗效评价参照《中药新药治疗急性胰腺炎的临床研究指导原则》制定。
(1)痊愈:3天内症状、体征缓解,7天内消失,血、尿淀粉恢复正常;
(2)显效:7天内症状、体征显著好转,14天内消失,血、尿淀粉晦恢复正常;
(3)有效:7天内症状、体征减轻,14天内消失,血、尿淀粉酵有下降趋势;
(4)无效:7天内症状、体症未减轻或恶化,血、尿淀粉酶未降低。
愈显率=(痊愈例数+显效例数)/总病例数×100%
1.2.4统计学方法
试验结束后,收集资料并进行统计和分析。对构成比采用行x列表的χ2检验(Chi-5quaretest),计量资料以均数士标准误(M±se)表示,组间比较用t检验,等级资料采用Ridit分析,P<0.05为差异显著,P<0.01差异非常显著,全部数据用GraphPad5.0统计软件分析处理。
2.结果
2.1两组临床症状比较
与对照组比较,治疗组首次排便时间及腹部压痛消失时间均明显缩短(P<0.01,P<0.05),有统计学差异;腹痛消失时间较对照组也有缩短,但无显著性差异。(见表3)
表3两组患者临床症状比较(M±se)
与对照组比较,**:P<0.01,*:P<0.05
2.2两组实验室检查比较
与对照组比较,治疗组血淀粉酶及白细胞计数恢复正常时间有所减少,但无显著性差异(P>0.05);治疗组CRP恢复正常时间与对照组比较明显缩短,有统计学差异(P<0.05)。(见表4)
表4两组患者实验室检查结果比较(M±se)
与对照组比较,*:P<0.05
2.3两组愈显率比较
治疗组痊愈14例,显效14例,有效3例,无效0例,对照组痊愈9例,显效11例,有效8例,治疗组愈显率明显优于对照组(P<0.05)。(见表5)
表5两组患者愈显率比较
与对照组比较,*:P<0.05
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (5)
1.一种治疗胰腺炎的中药组合物,其特征在于,所述中药组合物是由如下所述重量份的原料药制成:大黄20份、芒硝15份、枳实15份、厚朴15份、桃仁l5份、丹参15份。
2.权利要求1所述中药组合物在制备治疗胰腺炎的药物中的应用。
3.根据权利要求2所述的药物,其特征在于,所述药物的剂型为中药汤剂,通过灌肠给药。
4.根据权利要求2所述的药物,其特征在于,所述胰腺炎为急性胰腺炎。
5.根据权利要求2所述的药物,其特征在于,所述药物还包括药学上允许的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710286315.0A CN106913669B (zh) | 2017-04-27 | 2017-04-27 | 一种治疗胰腺炎的中药组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710286315.0A CN106913669B (zh) | 2017-04-27 | 2017-04-27 | 一种治疗胰腺炎的中药组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106913669A CN106913669A (zh) | 2017-07-04 |
CN106913669B true CN106913669B (zh) | 2020-05-19 |
Family
ID=59568228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710286315.0A Expired - Fee Related CN106913669B (zh) | 2017-04-27 | 2017-04-27 | 一种治疗胰腺炎的中药组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106913669B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114432373A (zh) * | 2022-03-08 | 2022-05-06 | 宫玉娥 | 一种治疗胰腺炎的外用中药 |
-
2017
- 2017-04-27 CN CN201710286315.0A patent/CN106913669B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
加味大承气汤治疗急性胆源性胰腺炎29例;李俊达等;《中国中西医结合杂志》;20040731;第24卷(第7期);第657-658页 * |
通腑活血方对伴高脂血症性重症急性胰腺炎降脂的临床观察;时枫等;《新中医》;20070531;第39卷(第5期);第40-41页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106913669A (zh) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03003446A (es) | Nueva composicion herbacea medicinal para tratar enfermedades del higado y vih. | |
WO2022036779A1 (zh) | 化湿败毒颗粒及其制备方法和抗病毒药物 | |
CN101121013A (zh) | 治疗顽固性口腔溃疡、白塞氏病、干燥综合症药物及制法 | |
CN104800773B (zh) | 一种用于防治新产奶牛子宫疾病的中药组合物及其制备方法 | |
CN102058847A (zh) | 一种治疗盆腔疾病的中药组合物及其制备方法和应用 | |
CN103223069A (zh) | 一种治疗肝炎的中药组合物 | |
CN106913669B (zh) | 一种治疗胰腺炎的中药组合物及其应用 | |
CN104225472B (zh) | 一种治疗口腔粘膜病变的中药制剂及制备方法和用途 | |
CN104491459A (zh) | 一种治疗肿瘤的中药组合物 | |
CN105233150A (zh) | 一种中药组合物及其应用 | |
CN108355124B (zh) | 一种治疗气道粘液高分泌的中药组合物及其应用 | |
CN101693084B (zh) | 一种治疗胃脘痛阴虚证的药物组合物及其制备方法 | |
CN101019981B (zh) | 一种中药制剂及其制备方法 | |
CN103800736B (zh) | 一种治疗高血压肾病的药物组合物及其应用 | |
CN102698064B (zh) | 一种治疗更年期综合征的药剂 | |
CN1265818C (zh) | 水蛭胶囊 | |
CN116370596B9 (zh) | 一种治疗胆道疾病的中药组合物 | |
CN115814040B (zh) | 一种治疗类风湿关节炎的中药组合物及其制剂 | |
CN114848746B (zh) | 具有抗高尿酸血症和痛风性关节炎作用的中药复方及其制备方法和应用 | |
CN117180379B (zh) | 一种治疗气虚毒滞型桥本甲状腺炎的中药组合物及其应用 | |
CN112138105B (zh) | 一种治疗支气管扩张症肺脾气虚、痰湿阻肺证的中药组合物及其应用 | |
CN115624560B (zh) | 一种治疗慢性肾功能衰竭的中药有效成分复方及其应用 | |
CN111228366B (zh) | 治疗病毒性肺炎的中药组合物 | |
CN105641057A (zh) | 一种治疗脾不统血型原发性肾小球性血尿的药物组合物 | |
CN105250952B (zh) | 一种治疗子宫腺肌症的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200519 |